

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ARKINSTALL

In re Application of:

Stephen ARKINSTALL et al

Appln. No.: 10/070,954

Filed: July 22, 2002

For: PHARMACEUTICALLY ACTIVE

SULFONAMIDE DERIVATIVES

Conf. No.: 4903

Art Unit: 1614

Examiner:

Washington, D.C.

April 14, 2003

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed:

(Check one of the boxes A-D)

- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office

} } action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

[] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "i" below).

(Check one of the boxes "i" and "ii" below:)

- [] i. Counsel certifies that, upon information and belief, each item of information listed herein was either
 - [] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
 - [] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in \$1.56(c) more than three months prior to the filing of this IDS.

(use one and delete other of following)

- [] ii. A check (check no. _____) for the fee set forth in \$1.17(p), presently believed to be \$180, is enclosed. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.
- [] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in \$1.17(p), presently believed to be \$180. If the enclosed payment is incorrect,

please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.

[] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) state as follows under 37 CFR §1.97(e) for consideration of this IDS, that, upon information and belief, each item of information listed herein was either

(Check one of the boxes "a" and "b" below)

- [] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- [] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in \$1.56(c) more than three months prior to the filing of this IDS.

(use one and delete other of following and this note)

A check (check no. _____) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in \$1.17(i), presently believed to be \$180 is enclosed. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate)

[] A	A. Document(s)	is	(are)	deemed
substantially o	cumulative to document(s)			and,
in accordance v documents is en	with \$1.98(c), only a copy of nclosed.	each	of the	latter
[] E	3. Certain documents were prev	/ious	ly cited	d by or
	ne Office in the following pried upon under 35 U.S.C. 120:	ior a	oplicat:	ion(s),
	numbers and filing dates of p	rior	applica	tions)
copies of the f	dentifies these documents by forms PTO-892 and PTO-1449 fro tion(s) or a fresh PTO-14	m the	e files	of the
	request that they be consicordance with \$1.98(d). Per			
	ese documents need not be			
application.				
ı i a	3. Document(s)is	(are) not	in the
	lage. In accordance w			
Applicant(s) st			51,00	(4) (5),
c (An English translation of each (or of the pertinent portion copy of each corresponding patent or application, or abstract (or claim) is enclosed	ns th End End	nereof), glish-la	or a anguage
	A concise explanation of document(s) is found	d in	the at	ttached
	(see reply to Comment 68 in the final rules; 1135 OG 13 at 20)	_	reamble	to the
	A concise explanation of document(s) is set for			
(ins	sert concise explanation of rel	levan	ce)	

In re Appln. No. 70/070,954

[] A concise explanation of the relevance of document(s) can be found on page(s) ____ of the specification.

- [] A concise explanation of document(s) can be found on the attached sheet.
- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [] 5. Other information being provided for the examiner's consideration follows:

(insert other information)

6. In accordance with 37 CFR §\$1.97(g) and (h), filing of this IDS should not be construed as representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

No. 25,618

RLB:rd

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202) 628-5197 Facsimile: (202)737-3528 Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OT APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	10/070,954				
Filing Date	July 22, 2002				
First Named Inventor	Stephen ARKINSTALL				
Group Art Unit	1614				
Examiner Name					
Attorney Dealest Number	ADVINISTAL I =1				

· <u>/</u>							
1	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	U.S. Patent Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
_							
						M.	
					,	\$7.	
						Z & Q	
						<u> </u>	
						8 5 1	
						2003	
						\$ \times \tag{\alpha}	
						8 6	

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Number				Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Office ³	Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD- YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
	AS	wo	01/23379	A1	Applied Res Systems	04-05-2001		
	AT	wo	01/23382	A1	Applied Res Systems	04-05-2001		
								ļ
					•			

Examiner	Date	•
Signature	Considered	
		_

OIPE

AFK | 4 ZUU

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.